Celebrex (celecoxib), the first COX-2 selective NSAID to hit the market

Patients are asking about Celebrex (celecoxib), the first COX-2 selective NSAID to hit the market.

It'll be co-promoted by Searle and Pfizer.

Celebrex is approved for rheumatoid and osteoarthritis. It's as effective as other NSAIDs for joint pain and swelling.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote